Assistance Publique des Hôpitaux de Paris SA
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Private
- Established
- 1849-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.aphp.fr
Clinical Trials
3.3k
Active:99
Completed:1511
Trial Phases
6 Phases
Early Phase 1:1
Phase 1:88
Phase 2:263
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2061 trials with phase data)• Click on a phase to view related trials
Not Applicable
1205 (58.5%)Phase 3
391 (19.0%)Phase 2
263 (12.8%)Phase 4
113 (5.5%)Phase 1
88 (4.3%)Early Phase 1
1 (0.0%)"Randomized Controlled Trial Testing the Efficacy of Corticosteroid Therapy Versus Placebo in Fibrotic Hypersensitivity Pneumonitis"
Not Applicable
Not yet recruiting
- Conditions
- Hypersensitivity Pneumonitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-07
- Last Posted Date
- 2025-10-07
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 120
- Registration Number
- NCT07210008
Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center
Recruiting
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)Immune Thrombotic Thrombocytopenic PurpuraThrombotic MicroangiopathiesMicroangiopathy, ThromboicCardiovascular DiseasesAutoimmune DiseasesRare DiseasesNeurological Manifestations
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 1200
- Registration Number
- NCT07205861
- Locations
- 🇫🇷
Service d'Hématologie Hôpital Saint-Antoine, Paris, France
Impact of Real-time MIC (Minimum Inhibitory Concentration) Reporting (<6 Hours) on β-lactam Prescription in Cases of Gram-negative Bacilli Bacteremia in ICU Patients in Real-life Settings
Not Applicable
Not yet recruiting
- Conditions
- Gram-negative BacteremiaIntensive Care Patients
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 200
- Registration Number
- NCT07202377
Combined Gastrointestinal Decontamination in Acute Severe Poisoning
Not Applicable
Not yet recruiting
- Conditions
- Severe Poisoning With Cardiotropic or Psychotropic DrugAdmission to Intensive Care
- Interventions
- Drug: Combination of activated charcoal with polyethylene glycol for digestive decontaminationDrug: Standard Treatment (Guideline-Based)
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 200
- Registration Number
- NCT07201311
- Locations
- 🇫🇷
Sebastian Voicu, Paris, France
Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Not Applicable
Not yet recruiting
- Conditions
- GVHD - Graft-Versus-Host DiseaseHSCTHaploidentical Stem Cell Transplantation
- Interventions
- Drug: Cyclophosphamide 35mg/kg/dayDrug: Cyclophosphamide 50mg/kg/day
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 180
- Registration Number
- NCT07193420
- Locations
- 🇫🇷
Saint Antoine Hospital - Hematology Department, Paris, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 666
- Next
News
AB Science Secures US Patent for Masitinib in Sickle Cell Disease Treatment Until 2040
AB Science has received a Notice of Allowance from the US Patent Office for masitinib in treating sickle cell disease, providing intellectual property protection until November 2040.
Dual Blood Pressure Medication Strategy Halves Arterial Events in vEDS Patients
A Phase 3 ARCADE trial demonstrates that combining irbesartan with celiprolol reduces severe arterial events by 50% in vascular Ehlers-Danlos syndrome patients over two years.